VivoSim Labs (NASDAQ:VIVS) Stock Price Down 0.8% – What’s Next?

VivoSim Labs, Inc. (NASDAQ:VIVS) shares dropped 0.8% on Wednesday . The company traded as low as $1.1455 and last traded at $1.18. Approximately 15,132 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 52,297 shares. The stock had previously closed at $1.19.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, VivoSim Labs currently has an average rating of “Sell”.

VivoSim Labs Price Performance

The stock’s 50-day simple moving average is $1.39 and its two-hundred day simple moving average is $1.79.

Hedge Funds Weigh In On VivoSim Labs

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP bought a new position in VivoSim Labs, Inc. (NASDAQ:VIVS) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 8.23% of the company’s stock.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.